[
    [
        {
            "time": "",
            "original_text": "锁定翻倍大牛股：浮盈最高逾216% 公募参与定增规模突增548%",
            "features": {
                "keywords": [
                    "翻倍",
                    "牛股",
                    "浮盈",
                    "公募",
                    "定增",
                    "规模突增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "锁定翻倍大牛股：浮盈最高逾216% 公募参与定增规模突增548%",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-06-02",
            "original_text": "康泰生物：97.4万股限售股6月2日上市流通 解禁",
            "features": {
                "keywords": [
                    "康泰生物",
                    "限售股",
                    "解禁",
                    "上市流通"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：97.4万股限售股6月2日上市流通 解禁",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-06-02",
            "original_text": "康泰生物(300601.SZ)：97.44万股限制性股票6月2日解禁 解禁",
            "features": {
                "keywords": [
                    "康泰生物",
                    "限制性股票",
                    "解禁"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)：97.44万股限制性股票6月2日解禁 解禁",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]